Macquarie Group’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Macquarie Group’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,506	Closed	-$70K	–	2198
2022 Q3	$70K	Sell	1,506 -1,262	-46%	-$35K	﹤0.01%	1858
2022 Q2	$84K	Buy	2,768 +936	+51%	+$27.9K	﹤0.01%	1914
2022 Q1	$60	Hold	1,832	–	–	﹤0.01%	2081
2021 Q4	$48K	Buy	1,832 +1,238	+208%	+$95.8K	﹤0.01%	2176
2021 Q3	$60K	Buy	594 +223	+60%	+$26.1K	﹤0.01%	2175
2021 Q2	$53K	Sell	371 -360	-49%	-$40.7K	﹤0.01%	2150
2021 Q1	$73K	Sell	731 -220	-23%	-$25.7K	﹤0.01%	1988
2020 Q4	$118K	Sell	951 -209	-18%	-$27.5K	﹤0.01%	1829
2020 Q3	$113K	Sell	1,160 -7,590	-87%	-$948K	﹤0.01%	1750
2020 Q2	$1.36M	Sell	8,750 -3,011	-26%	-$458K	﹤0.01%	1124
2020 Q1	$1.7M	Hold	11,761	–	–	﹤0.01%	960
2019 Q4	$2.4M	Buy	+11,761	New	+$2.15M	﹤0.01%	983

Other funds holding RETA

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Macquarie Group's RETA Position: Q4 2022 in Review

Macquarie Group sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2022, closing a stake of 1,506 shares — an estimated $70K sold.

Macquarie Group first reported a position in RETA in Q4 2019 and held it in 12 quarters. The position peaked at $2.4M in Q4 2019. 168 funds tracked by Wall St. Rank hold RETA as of Q4 2022.

Macquarie Group reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 1,506 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2022, an estimated $70K.
Macquarie Group first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q4 2019 and held it in 12 quarters.
Macquarie Group's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $2.4M in Q4 2019.
168 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.